Latest Blueprint Medicines News & Updates

See the latest news and media coverage for Blueprint Medicines. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Blueprint Medicines

Global biopharmaceutical company

blueprintmedicines.com
Headquarters
Cambridge, United States
Founded year
2011
Company type
Public company
Number of employees
700–1,000

Latest news about Blueprint Medicines

Company announcements

  • Blueprint Medicines

    Blueprint Medicines announces four-year PIONEER data for AYVAKIT

    Data show sustained symptom control, quality of life improvement, and long-term safety in indolent systemic mastocytosis patients. Presented at 2026 AAAAI Annual Meeting.

  • Blueprint Medicines

    Blueprint Medicines highlights AYVAKIT long-term benefits at ASH

    Data from PIONEER and PATHFINDER trials show sustained symptom control, quality-of-life improvements, prolonged survival, and bone health benefits in ISM and advanced SM.

  • Blueprint Medicines

    Blueprint Medicines announces AYVAKIT data at EHA and EAACI

    Data from PIONEER, PATHFINDER, and EXPLORER trials reinforce sustained efficacy and safety in systemic mastocytosis treatment. Presentations include oral and flash talks.

  • Blueprint Medicines

    Sanofi agrees to acquire Blueprint Medicines

    The deal values Blueprint at $9.1 billion upfront, plus up to $0.6 billion in CVRs for BLU-808 milestones. It adds Ayvakit for systemic mastocytosis and immunology pipeline to Sanofi's portfolio.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Blueprint Medicines

Track Blueprint Medicines and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Blueprint Medicines competitors & trending companies

Browse news for competitors to Blueprint Medicines and other trending companies.